{
    "qwen-v2.5-14b-instruct": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "qwen-v2.5-14b-instruct",
            "response": [
                "Pembrolizumab (KEYTRUDA)",
                "Nivolumab (OPDIVO)",
                "Atezolizumab (TECENTRIQ)",
                "Durvalumab (IMFINZI)",
                "Cetuximab (ERBITUX)",
                "Docetaxel",
                "Osimertinib (TAGRISSO)",
                "Alectinib (ALECensa)",
                "Crizotinib (XALKORI)",
                "Necitumumab (PORTOLOM)",
                "Ramucirumab (CYRAMZA)",
                "Dacomitinib (VIZIMPRO)",
                "Amivantamab (Rybrevant)",
                "Selpercatinib (RETACRIT)",
                "Capmatinib (EXKIVITY)",
                "Brentuximab vedotin (ADCETRIS)",
                "Ipilimumab (YERVOY)",
                "Afatinib (GIOTRIF)",
                "Neratinib (Nerlynx)",
                "Larotrectinib (VITRAKVI)",
                "Tepotinib (TAK-788)",
                "Entrectinib (Rozlytrek)",
                "Sacituzumab govitecan (Trodelvy)"
            ]
        }
    ],
    "phi-v4": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "phi-v4",
            "response": [
                "Pembrolizumab (KEYTRUDA)",
                "Nivolumab (OPDIVO)",
                "Atezolizumab (TECENTRIQ)",
                "Durvalumab (IMFINZI)",
                "Sintilimab (TUFINTRUM)",
                "Ceritinib (ZENKERBA)",
                "Alectinib (ALEMTRA)",
                "Crizotinib (XALKORI)",
                "Lorlatinib (LORLATAB)",
                "Osimertinib (TAGRISSO)",
                "Erlotinib (Tarceva)",
                "Gefitinib (IRESSA)",
                "Afatinib (GOTIFULIN)",
                "Cetuximab (ERBITUX)",
                "Ramucirumab (CYRAMZA)",
                "Bevacizumab (AVASTIN)",
                "Pemetrexed (ALIMTA)",
                "Docetaxel (DOCETAXEL)",
                "Paclitaxel (PACLITAXEL)",
                "Vinorelbine (NIVARINE)",
                "Etoposide (ETOPOSPIDE)",
                "Cisplatin (CISPLATIN)",
                "Carboplatin (CARBOPLATIN)",
                "Pazopanib (VOTRIENT)"
            ]
        }
    ],
    "mistral-small-instruct-24B": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "mistral-small-instruct-24B",
            "response": [
                "Cisplatin (CDDP)",
                "Carboplatin",
                "Paclitaxel (Taxol)",
                "Docetaxel (Taxotere)",
                "Gemcitabine (Gemzar)",
                "Pemetrexed (Alimta)",
                "Erlotinib (Tarceva)",
                "Crizotinib (Xalkori)",
                "Atezolizumab (Tecentriq)",
                "Nivolumab (Opdivo)",
                "Pembrolizumab (Keytruda)",
                "Durvalumab (Imfinzi)",
                "Osimertinib (Tagrisso)",
                "Alectinib (Alecensa)",
                "Ceritinib (Zykadia)",
                "Brigatinib (Alunbrig)",
                "Lorlatinib (Lorbrena)",
                "Afatinib (Gilotrif)",
                "Bevacizumab (Avastin)",
                "Ramucirumab (Cyramza)",
                "Nintedanib (Ofev)",
                "Rucaparib (Rubraca)",
                "Olaparib (Lynparza)",
                "Dabrafenib (Tafinlar)"
            ]
        }
    ],
    "gemma-3": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "gemma-3",
            "response": [
                "Cisplatin (CIS)",
                "Carboplatin (CAR)",
                "Paclitaxel (PAC)",
                "Docetaxel (DOC)",
                "Gemcitabine (GEM)",
                "Vinorelbine (VIN)",
                "Pemetrexed (PEM)",
                "Erlotinib (ERL)",
                "Gefitinib (GEF)",
                "Afatinib (AFA)",
                "Osimertinib (OSI)",
                "Dacomitinib (DAC)",
                "Bevacizumab (BEV)",
                "Ramucirumab (RAM)",
                "Pembrolizumab (PEMB)",
                "Nivolumab (NIV)",
                "Atezolizumab (ATE)",
                "Durvalumab (DUR)",
                "Cemiplimab (CEM)",
                "Sotorasib (SOT)",
                "Mobocertinib (MOB)",
                "Amivantamab (AMI)",
                "Capmatinib (CAP)",
                "Selpercatinib (SEL)"
            ]
        }
    ],
    "gpt-4o": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "gpt-4o",
            "response": [
                "Gefitinib (IRESSA)",
                "Erlotinib (TARCEVA)",
                "Afatinib (GILOTRIF)",
                "Osimertinib (TAGRISSO)",
                "Alectinib (ALECENSA)",
                "Ceritinib (ZYKADIA)",
                "Crizotinib (XALKORI)",
                "Brigatinib (ALUNBRIG)",
                "Dabrafenib (TAFINLAR)",
                "Trametinib (MEKINIST)",
                "Pembrolizumab (KEYTRUDA)",
                "Nivolumab (OPDIVO)",
                "Atezolizumab (TECENTRIQ)",
                "Durvalumab (IMFINZI)",
                "Lorlatinib (LORBRENA)",
                "Sotorasib (LUMAKRAS)",
                "Capmatinib (TABRECTA)",
                "Tepotinib (TEPMETKO)",
                "Selpercatinib (RETEVMO)",
                "Pralsetinib (GAVRETO)",
                "Amivantamab (RYBREVANT)",
                "Mobocertinib (EXKIVITY)",
                "Ramucirumab (CYRAMZA)",
                "Entrectinib (ROZLYTREK)"
            ]
        }
    ],
    "gpt-4o-mini": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "gpt-4o-mini",
            "response": [
                "Erlotinib (Tarceva)",
                "Gefitinib (Iressa)",
                "Afatinib (Gilotrif)",
                "Osimertinib (Tagrisso)",
                "Crizotinib (Xalkori)",
                "Alectinib (Alecensa)",
                "Ceritinib (Zykadia)",
                "Brigatinib (Alunbrig)",
                "Lorlatinib (Lorbrena)",
                "Nivolumab (Opdivo)",
                "Pembrolizumab (Keytruda)",
                "Durvalumab (Imfinzi)",
                "Atezolizumab (Tecentriq)",
                "Ramucirumab (Cyramza)",
                "Docetaxel (Taxotere)",
                "Paclitaxel (Taxol)",
                "Vinorelbine (Navelbine)",
                "Bevacizumab (Avastin)",
                "Trametinib (Mekinist)",
                "Dabrafenib (Tafinlar)",
                "Lorlatinib (Lorbrena)",
                "Entrectinib (Rozlytrek)",
                "Selpercatinib (Lumakras)",
                "Tazemetostat (Tazverik)",
                "Talazoparib (Talzenna)"
            ]
        }
    ],
    "gpt-4-32k": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "gpt-4-32k",
            "response": [
                "Tarceva (Erlotinib)",
                "Tagrisso (Osimertinib)",
                "Xalkori (Crizotinib)",
                "Alecensa (Alectinib)",
                "Alunbrig (Brigatinib)",
                "Zykadia (Ceritinib)",
                "Opdivo (Nivolumab)",
                "Keytruda (Pembrolizumab)",
                "Tecentriq (Atezolizumab)",
                "Imfinzi (Durvalumab)",
                "Avastin (Bevacizumab)",
                "Cyramza (Ramucirumab)",
                "Gilotrif (Afatinib)",
                "Iressa (Gefitinib)",
                "Vizimpro (Dacomitinib)",
                "Portrazza (Necitumumab)",
                "Adcetris (Brentuximab vedotin)",
                "Zejula (Niraparib)",
                "Lynparza (Olaparib)",
                "Rubraca (Rucaparib)",
                "Yervoy (Ipilimumab)",
                "Retevmo (Selpercatinib)",
                "Gavreto (Pralsetinib)",
                "Lorbrena (Lorlatinib)"
            ]
        }
    ],
    "gpt-35-turbo-16k": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "gpt-35-turbo-16k",
            "response": [
                "Pembrolizumab (Keytruda)",
                "Nivolumab (Opdivo)",
                "Atezolizumab (Tecentriq)",
                "Durvalumab (Imfinzi)",
                "Alectinib (Alecensa)",
                "Crizotinib (Xalkori)",
                "Ceritinib (Zykadia)",
                "Osimertinib (Tagrisso)",
                "Erlotinib (Tarceva)",
                "Afatinib (Gilotrif)",
                "Gefitinib (Iressa)",
                "Brigatinib (Alunbrig)",
                "Bevacizumab (Avastin)",
                "Ramucirumab (Cyramza)",
                "Atezolizumab (Tecentriq)",
                "Necitumumab (Portrazza)",
                "Pembrolizumab (Keytruda)",
                "Nivolumab (Opdivo)",
                "Atezolizumab (Tecentriq)",
                "Durvalumab (Imfinzi)",
                "Crizotinib (Xalkori)",
                "Ceritinib (Zykadia)",
                "Osimertinib (Tagrisso)",
                "Erlotinib (Tarceva)",
                "Afatinib (Gilotrif)"
            ]
        }
    ],
    "o1-mini": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "o1-mini",
            "response": [
                "Cisplatin (CDDP)",
                "Carboplatin (CBDCA)",
                "Paclitaxel (PTX)",
                "Docetaxel (DTX)",
                "Pemetrexed (PEM)",
                "Vinorelbine (VNR)",
                "Gemcitabine (GEM)",
                "Topotecan",
                "Etoposide (VP-16)",
                "Erlotinib (ERL)",
                "Gefitinib (GEF)",
                "Afatinib (AFA)",
                "Osimertinib (OSI)",
                "Crizotinib (CRIZ)",
                "Alectinib (ALC)",
                "Brigatinib (BRIG)",
                "Ceritinib (CER)",
                "Lorlatinib (LRL)",
                "Bevacizumab (BEV)",
                "Ramucirumab (RAM)",
                "Nivolumab (NIVO)",
                "Pembrolizumab (PEMBRO)",
                "Atezolizumab (ATEZO)",
                "Durvalumab (DURV)"
            ]
        }
    ],
    "anthropic.claude-3-5-sonnet-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "anthropic.claude-3-5-sonnet-v1:0",
            "response": [
                "Erlotinib (Tarceva)",
                "Gefitinib (Iressa)",
                "Afatinib (Gilotrif)",
                "Osimertinib (Tagrisso)",
                "Crizotinib (Xalkori)",
                "Ceritinib (Zykadia)",
                "Alectinib (Alecensa)",
                "Brigatinib (Alunbrig)",
                "Lorlatinib (Lorbrena)",
                "Dabrafenib (Tafinlar)",
                "Trametinib (Mekinist)",
                "Pembrolizumab (Keytruda)",
                "Nivolumab (Opdivo)",
                "Atezolizumab (Tecentriq)",
                "Durvalumab (Imfinzi)",
                "Ramucirumab (Cyramza)",
                "Bevacizumab (Avastin)",
                "Necitumumab (Portrazza)",
                "Pemetrexed (Alimta)",
                "Docetaxel (Taxotere)",
                "Gemcitabine (Gemzar)",
                "Paclitaxel (Taxol)",
                "Vinorelbine (Navelbine)",
                "Topotecan (Hycamtin)"
            ]
        }
    ],
    "anthropic.claude-3-opus-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "anthropic.claude-3-opus-v1:0",
            "response": [
                "Alectinib (Alecensa)",
                "Atezolizumab (Tecentriq)",
                "Bevacizumab (Avastin)",
                "Brigatinib (Alunbrig)",
                "Capmatinib (Tabrecta)",
                "Ceritinib (Zykadia)",
                "Crizotinib (Xalkori)",
                "Dabrafenib (Tafinlar)",
                "Dacomitinib (Vizimpro)",
                "Docetaxel (Taxotere)",
                "Durvalumab (Imfinzi)",
                "Erlotinib (Tarceva)",
                "Gefitinib (Iressa)",
                "Gemcitabine (Gemzar)",
                "Ipilimumab (Yervoy)",
                "Lorlatinib (Lorbrena)",
                "Necitumumab (Portrazza)",
                "Nivolumab (Opdivo)",
                "Osimertinib (Tagrisso)",
                "Paclitaxel (Taxol)",
                "Pembrolizumab (Keytruda)",
                "Pemetrexed (Alimta)",
                "Ramucirumab (Cyramza)",
                "Selpercatinib (Retevmo)"
            ]
        }
    ],
    "anthropic.claude-3-sonnet-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "anthropic.claude-3-sonnet-v1:0",
            "response": [
                "Gefitinib (Iressa)",
                "Erlotinib (Tarceva)",
                "Afatinib (Gilotrif)",
                "Osimertinib (Tagrisso)",
                "Crizotinib (Xalkori)",
                "Ceritinib (Zykadia)",
                "Alectinib (Alecensa)",
                "Brigatinib (Alunbrig)",
                "Lorlatinib (Lorviqua)",
                "Dabrafenib (Tafinlar)",
                "Trametinib (Mekinist)",
                "Nivolumab (Opdivo)",
                "Pembrolizumab (Keytruda)",
                "Atezolizumab (Tecentriq)",
                "Durvalumab (Imfinzi)",
                "Ramucirumab (Cyramza)",
                "Necitumumab (Portrazza)",
                "Pemetrexed (Alimta)",
                "Gemcitabine (Gemzar)",
                "Vinorelbine (Navelbine)",
                "Docetaxel (Taxotere)",
                "Paclitaxel (Taxol)",
                "Nab-paclitaxel (Abraxane)"
            ]
        }
    ],
    "anthropic.claude-3-haiku-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "anthropic.claude-3-haiku-v1:0",
            "response": [
                "Osimertinib (OSIM)",
                "Erlotinib (ERLO)",
                "Gefitinib (GEFI)",
                "Afatinib (AFAT)",
                "Alectinib (ALEC)",
                "Brigatinib (BRIG)",
                "Ceritinib (CERI)",
                "Crizotinib (CRIZ)",
                "Dacomitinib (DACO)",
                "Lorlatinib (LORL)",
                "Necitumumab (NECI)",
                "Nivolumab (NIVO)",
                "Pembrolizumab (PEMB)",
                "Ramucirumab (RAMU)",
                "Atezolizumab (ATEZ)",
                "Durvalumab (DURV)",
                "Avelumab (AVEL)",
                "Bevacizumab (BEVA)",
                "Paclitaxel (PACL)",
                "Carboplatin (CARB)",
                "Cisplatin (CISP)",
                "Docetaxel (DOCE)",
                "Gemcitabine (GEMC)",
                "Pemetrexed (PEME)"
            ]
        }
    ],
    "meta.llama3-8b-instruct-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "meta.llama3-8b-instruct-v1:0",
            "response": [
                "Alimta (pemetrexed)",
                "Alecensa (alectinib)",
                "AstraZeneca's Tagrisso (osimertinib)",
                "Avastin (bevacizumab)",
                "Braftovi (encorafenib)",
                "Ceritinib",
                "Combination of paclitaxel and carboplatin",
                "Combination of pemetrexed and cisplatin",
                "Combination of pemetrexed and carboplatin",
                "Combination of vinorelbine and cisplatin",
                "Combination of vinorelbine and carboplatin",
                "Combination of gemcitabine and cisplatin",
                "Combination of gemcitabine and carboplatin",
                "Combination of docetaxel and cisplatin",
                "Combination of docetaxel and carboplatin",
                "Combination of paclitaxel and cisplatin",
                "Combination of paclitaxel and vinorelbine",
                "Combination of vinblastine and cisplatin",
                "Combination of vinblastine and carboplatin",
                "Combination of vinblastine and vinorelbine",
                "Combination of vinblastine and paclitaxel",
                "Combination of vinblastine and docetaxel",
                "Combination of vinblastine and gemcitabine",
                "Combination of vinblastine and pemetrexed"
            ]
        }
    ],
    "meta.llama3-70b-instruct-v1:0": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "meta.llama3-70b-instruct-v1:0",
            "response": [
                "Afatinib (BIBW 2992)",
                "Ceritinib (LK-79)",
                "Crizotinib (PF-02341066)",
                "Afatinib dimaleate (BIBW 2992U)",
                "Dacomitinib (PF-00299804)",
                "Nintedanib (BIBF 1120)",
                "Crizotinib (PF-02341066)",
                "Vandetanib (ZD-6474)",
                "Ceritinib (LK-79)",
                "Selumetinib (AZD6244)",
                "Motesanib (AMG 706)",
                "Sorafenib (BAY 43-9006)",
                "Vemurafenib (PLX-4032)",
                "Dabrafenib (GSK-2118436A)",
                "Trametinib (GSK-1120212)",
                "Cobimetinib (G-019477)",
                "Sonidegib (LDE-225)",
                "Rafimetinib (BAY 86939)",
                "Vismodegib (RG-7164)",
                "Tipifarnib (R-115777)",
                "Lenvatinib (E-3810)",
                "Regorafenib (BAY 73-4502)",
                "Masitinib (AB-1010)",
                "Neratinib (HKI-272)"
            ]
        }
    ],
    "amazon.titan-text-express-v1": [
        {
            "call": "limited-list-referents-from-selection-criteria",
            "context": {
                "selection_criteria": "[\"it is a drug\", \"it has been approved to treat lung cancer\"]",
                "n": "24",
                "domain": "medicine",
                "concept": "approved drug for lung cancer"
            },
            "model": "amazon.titan-text-express-v1",
            "response": "[\n        {\n            \"Referent\": \"Carboplatin\" (CP)\n        },\n        {\n            \"Referent\": \"Paclitaxel\" (PTX)\n        },\n        {\n            \"Referent\": \"Cisplatin\" (CPT)\n        },\n        {\n            \"Referent\": \"Docetaxel\" (DTX)\n        },\n        {\n            \"Referent\": \"Vinorelbine\" (VNR)\n        },\n        {\n            \"Referent\": \"Gemcitabine\" (GEM)\n        },\n        {\n            \"Referent\": \"Vinblastine\" (VBL)\n        },\n        {\n            \"Referent\": \"Etoposide\" (ETO)\n        },\n        {\n            \"Referent\": \"Irrinotecan\" (IRI)\n        },\n        {\n            \"Referent\": \"Topotecan\" (TOP)\n        },\n        {\n            \"Referent\": \"Capecitabine\" (CAP)\n        },\n        {\n            \"Referent\": \"Oxaliplatin\" (OXA)\n        },\n        {\n            \"Referent\": \"Bevacizumab\" (BVZ)\n        },\n        {\n            \"Referent\": \"Sorafenib\" (SOR)\n        },\n        {\n            \"Referent\": \"Erlotinib\" (ERT)\n        },\n        {\n            \"Referent\": \"Gefitinib\" (GFT)\n        },\n        {\n            \"Referent\": \"Afatinib\" (AFT)\n        },\n        {\n            \"Referent\": \"Nintedanib\" (NTD)\n        },\n        {\n            \"Referent\": \"Axitinib\" (AXT)\n        },\n        {\n            \"Referent\": \"Vandetanib\" (VDT)\n        },\n        {\n            \"Referent\": \"Crizotinib\" (CRZ)\n        },\n        {\n            \"Referent\": \"Alectinib\" (ALC)\n        },\n        {\n            \"Referent\": \"Ceritinib\" (CER)\n        },\n        {\n            \"Referent\": \"Brigatinib\" (BRG)\n        }\n    ]"
        }
    ]
}